Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis

Anna Södergren1,2*, Kjell Karp3, Christine Bengtsson1,4, Bozena Möller5, Solbritt Rantapää-Dahlqvist1, Solveig Wällberg-Jonsson†

1 Department of Public Health and Clinical Medicine/Rheumatology, University of Umeå, Umeå, Sweden, 2 Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden, 3 Department of Surgical and Perioperative Sciences, University of Umeå, Umeå, Sweden, 4 Department of Rheumatology, Kristianstad Hospital, Kristianstad, Sweden, 5 Department of Rheumatology, Sunderby Hospital, Luleå, Sweden

† Deceased.
* anna.sodergren@umu.se

Abstract

Objectives
Patients with rheumatoid arthritis (RA) have an increased mortality and morbidity due to cardiovascular disease (CVD). In this prospective 5-year follow up of patients with RA, we analysed several biomarkers, known to be associated with atherosclerosis and/or inflammation in the general population. The aim of this study was to find out whether the RA-disease per se affect these biomarkers and if those could be associated with the progression of atherosclerosis, as measured by intima media thickness (IMT) among patients with early RA.

Methods
Patients from northern Sweden diagnosed with early RA, are consecutively recruited into an ongoing prospective study on CVD comorbidity. A subgroup of patients, aged ≤ 60 years (n = 71) was included for ultrasound measurements of IMT at inclusion (T0) and after 5 years (T5) together with age-sex-matched controls (n = 40). The patients were clinically assessed. Blood was analysed for lipids, ESR and CRP and several biomarkers known to be associated with atherosclerosis.

Results
At T0, the patients with RA had significantly lower levels of MIF and significantly higher levels of interleukin (IL)-18 and MIC-1 compared with controls. At T5, the patients with RA had significantly higher levels of pentraxin3, MIC-1, TNF-R2, ICAM-1, VCAM-1 and endostatin compared with controls. At T0 the levels of MPO correlated with DAS28, sCD40L with CRP and IL-18 with systolic blood pressure and Reynolds risk score. Using PLSR on a CVD-panel analysed with multiplex immunoassay, the patients with RA could be correctly classified into those who had a worsening in their IMT over the five years or not. Here, MMP3 was identified as influential.
Conclusions

This study indicates that the RA disease itself could affect several of the biomarkers in this study, and possibly also the processes involved in the development of atherosclerosis.

Introduction

Patients with rheumatoid arthritis (RA) have an increased atherosclerosis compared with the general population [1–5]. Atherosclerosis is now recognised as an inflammatory disease per se, and the two diseases, atherosclerosis and RA, are considered to share many similarities [6], albeit the link between them is, as yet, not evident. Even though, all stages of the atherogenic process appear to be enhanced in RA, all the way to increased incidence of cardiovascular disease (CVD) events [7, 8].

Sub-clinical atherosclerosis precedes CVD and an increased intima media thickness (IMT), measured by ultrasonography, is regarded to be an early indicator of a generalized atherosclerosis [9, 10]. We, and others, have previously shown that patients with established RA have a premature atherosclerosis as measured by an increased IMT of the common carotid artery (CCA) compared with controls [11–13]. However, this ultrasound measured indicator is not easily available and, further, has disadvantages like lack of possibility to detect the very early phases of the development of atherosclerosis. Therefore, to increase both the benefits of health and cost effectiveness, it is important to enhance the accuracy of the identification of the individuals at risk for increased atherosclerosis and subsequently CVD. In recent years, an interest has been growing to identify new molecular mechanisms associated with the developmental process of atherosclerosis [14]. The identification of such new biomarkers may improve the prediction of cardiovascular events and death.

In an inception cohort of patients with RA, we analysed several biomarkers, known to be associated with atherosclerosis and/or inflammation in the general population, and also known to be associated with subclinical atherosclerosis and traditional CVD risk factors. The aim of this study was to find out whether the RA-disease per se affects biomarkers known to be associated with atherosclerosis in the general population. Further, to find out whether these biomarkers are associated with the progression of subclinical atherosclerosis among patients with early RA.

Material and methods

Patients and controls

As described in detail previously [15–17] this study is a part of a continuing structured programme involving patients with early RA from Northern Sweden for the prospective analysis of the development of CVD using the nationwide Swedish Rheumatology Quality Register (SRQ). All eligible patients with newly diagnosed RA (i.e., fulfilling the ACR criteria) [18] and being symptomatic for no longer than 12 months are continuously enrolled into the register. Between 2000 and 2004 all patients under 60 years of age from the three most northern counties of Sweden were consecutively invited to participate in an extended survey on CV morbidity. Five years after inclusion into the study (T5), 71 of the 79 patients with RA originally included were willing to participate in the follow-up study, and 40 of the original 44 controls were reassessed. The controls (one control for two patients, but in 13 cases one control per patient) were matched for age (±5 years) and sex. Descriptive data in patients with RA and
controls are presented in Table 1 and have been published previously in more detail [15]. The DMARDs the patients received at T0 were; methotrexate in 37 cases, sulphasalazine in 10, oral gold in one, eight patients were receiving a combination of methotrexate and hydroxychloroquine phosphate, three a combination of methotrexate and sulphasalazine, two a combination of methotrexate, sulphasalazine and hydroxychloroquine phosphate and one had a combination of methotrexate, sulphasalazine and etanercept. During the five years of follow up 66 patients had been treated with methotrexate (mean number of months = 47), 36 with sulphasalazine (mean number of months = 31), 20 with hydroxychloroquine phosphate (mean number of months = 20), 11 with gold salt (mean number of months = 37), 13 with anti-TNF (mean number of months = 14), one with rituximab for 24 months and 14 with other DMARDs (mean number of months = 21). Some of the patients were treated with a combination of these drugs. All individuals gave their oral and written consent in accordance with the Declaration of Helsinki. The study was approved by the Regional Ethics Committee of Umeå University, Umeå, Sweden.

Physical examination and surveys

All patients were examined clinically at their inclusion into the study and regularly thereafter for disease activity according to DAS28 [21]. The examinations have been previously described in detail [15]. Moreover, European Systematic Coronary Risk Evaluation (SCORE) [19] and Reynolds Risk Score [20] were calculated at both T0 and T5. These compound measures of CVD risk factors indicate the risk of death due to CVD (SCORE) and the risk of a CV event (Reynolds Risk Score) during the next 10 years. In addition to the traditional CVD risk factors, the Reynolds Risk Score also includes a measure of inflammation, i.e. C-reactive protein (CRP). When calculating the Reynolds Risk Score, all patients were regarded as being non-diabetic due to a lack of information regarding haemoglobin A1c concentrations.

Table 1. Demographic data, traditional cardiovascular risk factors and measures of disease activity in 71 patients with early RA and in age and sex-matched controls evaluated at both baseline (T0) and after 5 years (T5). Data are expressed as mean value (standard deviation) if not stated otherwise.

|                         | RA (n = 71) | Controls (n = 40) |
|-------------------------|------------|------------------|
|                         | At T0      | At T5            | At T0 | At T5 |
| Female, n (%)           | 61 (86)    | 32 (80)          |
| Age, years              | 51.5 (10.7)| 48.1 (10.9)      |
| Duration of symptoms, months | 16.1 (6.7) | —                |
| Rheumatoid factor, n (%)| 48 (67)    | —                |
| Intima media thickness, mm | 0.52 (0.13) | 0.58 (0.13)*** | 0.54 (0.13) | 0.60 (0.12)*** |
| Systolic blood pressure, mmHg | 123.5 (14.4) | 126.3 (13.9)*  | 117.7 (11.3) | 124.1 (12.1)*** |
| Cholesterol, mmol/L     | 5.5 (0.9)  | 5.3 (1.0)        | 5.3 (1.1) | 5.6 (1.1) |
| BMI, kg/m²               | 25.8 (4.0) | 25.7 (4.5)       | 25.1 (4.9) | 25.2 (4.2) |
| ESR, mm/h               | 17.5 (16.2)| 15.6 (11.9)      | —      | —      |
| CRP, mg/L               | 11.9 (10.8)| 7.7 (7.2)**      | —      | —      |
| DAS28                   | 3.5 (1.4)  | 3.1 (1.5)*       | —      | —      |
| SCORE [19]              | 0.9 (1.3)  | 1.4 (1.7)***     | 0.6 (0.7) | 1.6 (1.9)*** |
| Reynolds Risk Score [20] | 2.2 (3.3)  | 2.7 (3.3)        | —      | —      |

*p-value <0.05, using T0 as baseline, unless stated otherwise.

https://doi.org/10.1371/journal.pone.0220531.t001
Blood sampling

As described in detail previously [15–17] all patients and controls donated a blood sample at the time of both occasions for the ultrasound measurements, i.e., at T0 and T5, and serum was stored at -80˚C. After thawing, serum concentrations were measured using commercial sandwich enzyme-linked immunosorbent assays (ELISAs) of pentraxin 3 (ptx3) (R&D Systems, Abingdon, UK), interleukin (IL)-18 (MBL, Woburn, MA, USA) and macrophage inhibitory cytokine 1 (MIC-1) (BioVendor, Brno, Czech Republic). Serum concentrations of IL-6, monocyte migration inhibitory factor (MIF), myeloperoxidases (MPO) and soluble CD40 ligand (sCD40L) were measured using multiplexed Procarta immunoassays based on the LumineX technology (Affymetrix Inc). Serum concentrations of tumour necrosis factor receptor 1 and 2 (TNF-R1 and TNF-R2), endoglin, intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1) and endostatin were analysed using commercial ELISAs (R&D Systems, Minneapolis, MN, USA). As a pilot study 19 patients with RA and 10 matched controls, a multiplex immunoassay was used for analysing 92 biomarkers potentially associated with cardiovascular disease (Proseek Multiplex CVD I, Olink Bioscience AB, Uppsala, Sweden).

Ultrasound investigations

The patients with RA were included as soon as possible following a diagnosis of RA (T0), and were examined by ultrasound at mean (SD) of 16.2 (±6.6) months after the primary symptom of RA. The ultrasound examinations at the follow up (T5) were performed at mean (and median) 60 (SD 1.2; range 55–64) months after the initial examination. All examinations were performed by the same experienced investigator and described in detail in previous publications [15, 17].

Statistics

Differences in variables between patients with RA and matched controls were analysed using simple conditional logistic regression analyses. Comparisons within the RA patient group or within the control group were performed using the Mann-Whitney U-test, or for comparisons over time, the Wilcoxon paired test. Simple and multiple linear regression analyses were used to identify certain variables associated with the different biomarkers. Correlations were tested with Spearman rank correlation or Pearsons correlation, whenever appropriate. For the results from the multiplex immunoassay, first a partial least squares regression (PLSR) was performed, with two components, where the X-variables are scaled by dividing each variable by its standard deviation. Using the scores from the PLSR a k-means clustering with two centers (2-means) (with the Hartigan-Wong algorithm) was performed in order to discriminate between the two groups. The result was evaluated by plotting the scores from the PLSR, that is using the scores as y and x coordinates. Each observation was assigned a colour (red or blue) according to the cluster assigned to that observation. The numbers represent the true group of the observation, that is ideally all observations with one number should have the same colour. Based on results from previous publications, calculations showed that a sample size of 26 in each group would render 95% power to detect a difference in IMT of 0.1mm and SD of 0.1 mm [15]. For statistical analyses, p-values <0.05 were considered statistically significant. Occasional missing values were regarded being at random. All calculations, except the PLSR, were made using SPSS 21.0 (SPSS Inc, Chicago, US).
Results

Patients with RA compared with controls

At T0, the patients with RA had significantly lower levels of MIF and significantly higher levels of IL-18 and MIC-1 compared with controls (Table 2). At T5, the patients with RA had significantly higher levels of pentraxin3, MIC-1, TNF-R2, ICAM-1, VCAM-1 and endostatin compared with controls (Table 2). The biomarkers included in the multiplex CVD-panel did not separate patients with RA from controls (Fig 1).

T5 compared with T0

The patients with RA had significantly lower levels of MIF and MPO at T5 compared with at T0 (Table 2). Among the controls, a statistically significant change between T0 and T5 was evident for MIF and pentraxin-3 (Table 2).

Table 2. Concentrations of biomarkers important for CVD in 71 in patients with early RA and in 40 age and sex-matched controls evaluated at both baseline (T0) and after 5 years (T5). Data are expressed as mean value (standard deviation).

| Biomarker       | RA          | Controls    |
|-----------------|-------------|-------------|
|                 | At T0       | At T5       | At T0       | At T5       |
| IL-6 (pg/mL)    | 13.2 (22.0) | 14.4 (27.6) | 6.1 (3.3)   | 6.9 (2.5)   |
|                 | n = 70      | n = 66      | n = 38      | n = 40      |
| MIF (pg/mL)     | 504.5 (328.6) xx | 398.7 (152.3) * | 882.4 (469.9) | 496.5 (164.9) *** |
|                 | n = 70      | n = 66      | n = 38      | n = 40      |
| MPO (pg/mL)     | 212.0 (116.6) | 173.8 (77.3) * | 207.4 (109.1) | 178.5 (56.8) |
|                 | n = 70      | n = 66      | n = 38      | n = 40      |
| sCD40L (pg/mL)  | 21.9 (7.3)  | 22.6 (7.0)  | 23.6 (6.5)  | 40.4 (56.4) |
|                 | n = 66      | n = 66      | n = 38      | n = 40      |
| pentraxin3 (ng/mL) | 1.16 (1.0) xx | 1.00 (0.5) xx | 1.3 (0.4)  | 0.69 (0.3) *** |
|                 | n = 66      | n = 63      | n = 35      | n = 37      |
| IL-18 (pg/mL)   | 344.4 (111.2) x | 356.2 (118.4) | 286.2 (94.4) | 303.4 (92.1) |
|                 | n = 70      | n = 66      | n = 38      | n = 39      |
| MIC-1 (ng/mL)   | 1.8 (1.2) x | 1.9 (0.9) xx | 1.2 (0.4)  | 1.3 (0.4)  |
|                 | n = 70      | n = 66      | n = 38      | n = 40      |
| TNF-R1 (ng/mL)  | 0.9 (0.7)   | 0.9 (0.7)   | 0.8 (0.6)   | 0.8 (0.6)   |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |
| TNF-R2 (ng/mL)  | 7.4 (6.9) xxx | 7.4 (6.9) xxx | 4.4 (1.1)  | 4.4 (1.1)  |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |
| Endoglin (ng/mL)| 93.6 (12.5) | 93.6 (12.5) | 11.6 (13.2) | 11.6 (13.2) |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |
| sICAM-1 (ng/mL)| 189.5 (40.5) x | 189.5 (40.5) x | 178.5 (30.6) | 178.5 (30.6) |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |
| sVCAM-1 (ng/mL)| 365.7 (94.2) x | 365.7 (94.2) x | 325.7 (8.3) | 325.7 (8.3) |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |
| Endostatin (ng/mL)| 121.9 (21.1) x | 121.9 (21.1) x | 111.9 (21.2) | 111.9 (21.2) |
|                 | n = 67      | n = 67      | n = 40      | n = 40      |

* p<0.05 compared to T0
**p<0.01 compared to T0
***p<0.001 compared to T0
x p<0.05 compared to controls
xx p<0.01 compared to controls
xxx p<0.001 compared to controls

https://doi.org/10.1371/journal.pone.0220531.t002
Correlations at T0

Among the patients with RA there were some correlations between the different biomarkers at T0 and markers of disease activity in RA or traditional CVD risk factors; MPO with DAS28 ($r = -0.4, p = 0.001$), sCD40L with CRP ($r = 0.3, p < 0.01$) and IL-18 with systolic blood pressure ($r = 0.3, p < 0.05$) as well as with Reynolds risk score ($r = 0.4, p < 0.05$).

Correlations between the different biomarkers

The correlations between the different biomarkers are presented in S1 Table.

Correlations at T5

Also after 5 years of follow up there were correlations between the different biomarkers and markers of disease activity or CVD risk factors; MPO with BMI ($r = 0.3, p < 0.05$) and CRP ($r = 0.3, p < 0.05$), IL-18 with smoking ($r = 0.4, p < 0.001$), MIC-1 with age ($r = 0.4, p < 0.001$), smoking ($r = 0.4, p < 0.001$), BMI ($r = 0.4, p < 0.01$), SCORE ($r = 0.3, p < 0.05$), Reynolds risk score ($r = 0.4, p < 0.05$) and IMT ($r = 0.3, p < 0.05$), TNF-R2 with ESR ($r = 0.3, p < 0.05$), endoglin with ESR ($r = -0.3, p < 0.05$) and DAS28 ($r = -0.4, p < 0.05$), sICAM-1 with Reynolds risk score ($r = 0.4, p < 0.05$).
score \( r = 0.6, \ p < 0.001 \) and IMT \( r = 0.3, \ p < 0.05 \) as well as sVCAM-1 with Reynolds risk score \( r = 0.4, \ p < 0.05 \).

Using PLSR on the CVD-panel analysed with multiplex, the patients with RA could be correctly classified into those who had a worsening in their IMT over the five years of follow up or not (Fig 2). Here, MMP3 was identified as influential. However, using data from the same CVD-panel, the patients with RA and IMT at T5 over/under median value could not be classified correctly with the biomarkers included (Fig 3). Also, none of the included biomarkers was identified as influential.

**Associations between biomarkers and IMT**

In simple regression analysis, none of the biomarkers were associated with IMT at T0 but some at T5 (Table 3). Only MIF was significantly associated with the change in IMT between T0 and T5 \( (\beta = -0.01, \ 95\% CI [-0.0001; -0.001], \ p\text{-value} = 0.036) \), although this association was not significant after adjustment for sex and age.

**Discussion**

Biomarkers of systemic inflammation, pro-inflammatory cytokines and chemokines have been suggested to be closely related to the atherosclerotic process. In this study we aimed to investigate some of these biomarkers, known to be associated with atherosclerosis and CVD in the general population, in a well characterised inception cohort of patients with early RA with data on prospective development of atherosclerosis. We found most of these potential biomarkers...
to be affected by the RA-disease itself, and therefore hard to identify as biomarkers of atherosclerosis in this setting. Among patients with RA, the area of surrogate endpoints is also difficult to interpret since several biomarkers of CVD are associated with general inflammation. Atherosclerosis is nowadays recognized as an inflammatory disease and there are many parallels between the pathological and immunological processes that occur in the synovium and the atheromatous lesions in the vessel walls [6]. A previous published study on the same individuals as in this study has suggested lipoprotein-associated phospholipase A2 (Lp-PLA2) as one of the biomarkers that might be able to indicate that, over time, the deleterious disease process in RA may also affect the vascular walls [16].

In this study, a few of the measured biomarkers that were associated with subclinical atherosclerosis. One of these, with significant different levels in patients with RA compared with controls, was MIF, that was significantly lower among patients with RA at T0, and also

Table 3. Simple regression analysis with IMT at T5 as dependent variable and biomarkers important for CVD as covariates in 71 patients with early RA.

| Variable          | β    | 95%CI       | p-value |
|-------------------|------|-------------|---------|
| sCD40L at T0      | 0.1/ pg/mL | 0.1;0.2   | 0.04*   |
| sICAM-1 at T5     | 0.2/ ng/mL | 0.0001;0.3 | 0.02*   |
| MIC-1 at T5       | 0.04/ ng/mL | 0.0001;0.1 | 0.01*   |

* None of these associations remained statistically significant after adjustment for sex and age

https://doi.org/10.1371/journal.pone.0220531.t003
decreased over the five years of follow up, both in patients with RA and controls. Our results are contrary to most other published studies since MIF is a cytokine with pleiotropic roles in both acute and chronic inflammatory diseases suggested to be associated with the progression and severity of atherosclerotic disease [22, 23].

Metalloproteinases are all suggested to be markers of vulnerable plaques [14] and in this study the biomarker of influence in separating those with and without progression of the atherosclerosis in a subgroup of the patients with RA was a metalloproteinase, MMP3. However, MMP3 is also involved in cartilage degradation and bone destruction in RA [24, 25], again pointing out the interlink between the diseases in the joint and the vessel wall.

Some of the other biomarkers showed statistically significant differences between patients with RA and controls or were correlated with disease activity. Most well-known are the cellular adhesion molecules (CAMs) that mediate adhesion of circulating leukocytes to endothelial cells, promoting subsequent transendothelial migration and formation of atheroma. In this study both ICAM-1 and VCAM-1 were correlated with risk for future CVD and ICAM-1 also with subclinical atherosclerosis, in line with previous studies [14]. Also the pro-inflammatory cytokine IL-18 was significantly higher among patients with RA compared with controls at baseline, in line with previous studies where IL-18 is suggested as a mediator of inflammation and angiogenesis in the joints in RA [26]. In this study, IL-18 was also associated with some traditional CVD risk factors, again supporting a link between these two processes [26]. Another biomarker indicating the same link is MIC-1, previously suggested to be a marker of erosive joint disease in RA [27] and also suggested to be associated with a common etiologic of RA and CVD [28]. In this study the levels of MIC-1 was higher in patients with RA compared with controls and associated with several traditional CVD risk factors. Another soluble biomarker regarded as a marker of plaque instability is sCD40L, that is produced by activated platelets [14] and regarded as marker of CVD risk in the general population [29]. In previous studies the levels of sCD40L, have been shown to be elevated in patients with RA [30, 31]. The association to CVD in patients with RA is still a matter of discussion [28, 30, 31]. In this study the level of sCD40L was correlated with disease activity at baseline and also associated with IMT five years later. The complicated and possible complex relationship between these biomarkers and inflammation is further illustrated in this study where the difference between patients with RA and controls changed over time, most evident for IL-18, MIF and pentraxin 3.

The main strength of the present study is its prospective design from disease onset. Data were collected from the onset of disease and then continuously during five years of follow up. In northern Sweden, practically all of the patients with newly diagnosed RA are included in a structured follow up programme. Of these patients, all aged ≤60 years were invited to participate in the present study within 12 months of their diagnosis.

The main limitation is the number of controls, and unfortunately it was not possible to include more controls. Furthermore, no variables of inflammation were available among the controls. The associations between these biomarkers and CVD must, however, be regarded as well studied in the general population. This study was directed at the interplay between biomarkers and other CVD risk factors among the patients with RA.

In conclusion, this study indicates that the RA disease itself might affect several of the biomarkers in this study, and possible also the processes involved in the development of atherosclerosis. Subsequently, none of the biomarkers in this study could explain the burden of subclinical atherosclerosis in these patients with early RA. Nevertheless, further studies are important for a better understanding of the premature atherosclerotic process in patients with inflammatory diseases like RA.
Supporting information

S1 Table. Correlations between different biomarkers important for CVD in 71 patients with early RA and in 40 age and sex-matched controls evaluated at both baseline (T0) and after 5 years (T5).

Acknowledgments

We thank Ms Elisabet Lundström at the Department of Surgical and Perioperative Sciences, University of Umeå, who carried out all of the ultrasound measurements. We also thank Ms Gun-Britt Johansson, Ms Ann-Chatrin Kallin and Ms Sonja Odeblom at the Department for Rheumatology, University Hospital, Umeå, for their excellent help with collection of patient data and Marie Eriksson, as well as Simon Vallin, Dept of Medicine, University Hospital, Umeå, for valuable statistical discussions.

Author Contributions

Conceptualization: Anna Södergren, Kjell Karp, Christine Bengtsson, Bozena Möller, Solbritt Rantapää-Dahlqvist, Solveig Wållberg-Jonsson.

Data curation: Anna Södergren, Christine Bengtsson, Bozena Möller, Solveig Wållberg-Jonsson.

Formal analysis: Anna Södergren, Solbritt Rantapää-Dahlqvist, Solveig Wållberg-Jonsson.

Funding acquisition: Anna Södergren, Solbritt Rantapää-Dahlqvist, Solveig Wållberg-Jonsson.

Investigation: Anna Södergren, Christine Bengtsson, Bozena Möller, Solveig Wållberg-Jonsson.

Methodology: Anna Södergren, Anna Södergren, Kjell Karp, Solveig Wållberg-Jonsson.

Project administration: Anna Södergren, Solveig Wållberg-Jonsson.

Resources: Anna Södergren, Kjell Karp, Christine Bengtsson, Solbritt Rantapää-Dahlqvist, Solveig Wållberg-Jonsson.

Validation: Christine Bengtsson, Bozena Möller, Solbritt Rantapää-Dahlqvist.

Writing – original draft: Anna Södergren.

Writing – review & editing: Anna Södergren, Kjell Karp, Christine Bengtsson, Bozena Möller, Solbritt Rantapää-Dahlqvist, Solveig Wållberg-Jonsson.

References

1. Wållberg-Jonsson S, Johansson H, Öhman ML, Rantapää-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999; 26(12):2562–71. Epub 1999/12/22. PMID: 10606363.

2. del Rincon I, Freeman G, Haas R, O’Leary D, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005; 52 (11):3413–23. https://doi.org/10.1002/art.21397 PMID: 16255018.

3. Dessein PH, Joffe BI, Veiler MG, Stevens BA, Tobias M, Reddi K, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol. 2005; 32(3):435–42. Epub 2005/03/03. doi: 0315162X-32-435[pai]. PMID: 15742434.

4. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011; 63(11):3216–25.
5. Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol. 2010; 30(5):1014–26. Epub 2010/02/13. doi: ATVAHA.109.198424 [pii] https://doi.org/10.1161/ATVAHA.109.198424 PMID: 20150560.

6. Klingenberg R, Luscher TF. Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison. Eur Heart J. 2015; 36(48):3423–5. Epub 2015/10/08. https://doi.org/10.1093/eurheartj/ehv489 PMID: 26443024; PubMed Central PMID: PMC4685179.

7. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59(12):1690–7. Epub 2008/11/28. https://doi.org/10.1038/ard.2008.190 PMID: 19035419.

8. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012; 71(9):1524–9. Epub 2012/03/20. https://doi.org/10.1136/annrheumdis-2011-200726 PMID: 22425941.

9. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115(4):459–67. Epub 2007/01/24. doi: CIRCULATIONAHA.106.628875 [pii] https://doi.org/10.1161/CIRCULATIONAHA.106.628875 PMID: 17242284.

10. Evans MR, Escalante A, Battafarano DF, Freeman GL, O’Leary DH, del Rincon I. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 2011; 63(5):1211–20. Epub 2011/02/10. https://doi.org/10.1002/art.30265 PMID: 21305526; PubMed Central PMID: PMC3286362.

11. Wållberg-Jonsson S, Backman C, Johnson O, Karp K, Lundstrom E, Sundqvist KG, et al. Increased prevalence of atherosclerosis in patients with medium term rheumatoid arthritis. J Rheumatol. 2001; 28(12):2597–602. Epub 2002/01/05. PMID: 11764203.

12. van Sijl AM, Peters MJ, Knot DK, de Vet HC, Gonzalez-Gay MA, Smulders YM, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011; 40(5):389–97. Epub 2010/10/05. doi: S0049-0172(10)00092-2 [pii] https://doi.org/10.1016/j.semarthritis.2010.06.006 PMID: 20889191.

13. Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, Di Minno MN. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015; 113(5):916–30. Epub 2015/02/27. https://doi.org/10.1160/TH14-11-0921 PMID: 25716931.

14. Kozeres L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis—the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology (Oxford). 2011; 50(11):1944–54. Epub 2011/07/15. doi: ker232 [pii] https://doi.org/10.1093/rheumatology/ker232 PMID: 21752870.

15. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. The Extent of Subclinical Atherosclerosis Is Partially Predicted by the Inflammation Load: A Prospective Study over 5 Years in Patients with Rheumatoid Arthritis and Matched Controls. J Rheumatol. 2015; 42(6):935–42. Epub 2015/04/17. https://doi.org/10.3899/jrheum.140694 PMID: 25877503.

16. Södergren A, Karp K, Bengtsson C, Möller B, Rantapää-Dahlqvist S, Wållberg-Jonsson S. Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis? BioMed research international. 2015; 2015:673018. Epub 2015/10/28. https://doi.org/10.1155/2015/673018 PMID: 26504820; PubMed Central PMID: PMC4609366.

17. Södergren A, Karp K, Boman K, Eriksson C, Lundstorm E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther. 2010; 12(4):R158. Epub 2010/08/18. doi: ar3116 [pii] https://doi.org/10.1186/ar3116 PMID: 20712865; PubMed Central PMID: PMC2945061.

18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315–24. Epub 1988/03/01. https://doi.org/10.1002/art.1780310302 PMID: 3358796.

19. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11):987–1003. Epub 2003/06/06. doi: S0195668X03001143 [pii] https://doi.org/10.1016/s0195-668x(03)00114-3 PMID: 12788299.

20. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297(6):611–9. Epub 2007/02/15. doi: 297/6/611 [pii] https://doi.org/10.1001/jama.297.6.611 PMID: 17299196.
21. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44–8. Epub 1995/01/01. https://doi.org/10.1002/art.1780380107 PMID: 7818570.

22. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 2008; 117(12):1594–602. Epub 2008/03/26. doi: 117/12/1594 [pii] https://doi.org/10.1161/CIRCULATIONAHA.107.729125 PMID: 18362243.

23. Morand EF, Leech M, Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature reviews Drug discovery. 2006; 5(5):399–410. Epub 2006/04/22. https://doi.org/10.1038/nrd2029 PMID: 16628200.

24. Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, et al. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci. 2010; 56(3):E98–107. Epub 2010/11/11. PMID: 21063156.

25. Galil SM, El-Shafey AM, Hagrass HA, Fawzy F, Sammak AE. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients. Int J Rheum Dis. 2016; 19(4):377–84. Epub 2014/10/09. https://doi.org/10.1111/1756-185X.12434 PMID: 25292349.

26. Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interfer on Cytokine Res. 2011; 31(10):745–51. Epub 2011/08/26. https://doi.org/10.1089/jir.2011.0050 PMID: 21864160.

27. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum. 2007; 56(3):753–64. Epub 2007/03/01. https://doi.org/10.1002/art.22410 PMID: 17328047.

28. Årlestig L, Rantapää-Dahlqvist S. Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease. J Rheumatol. 2012; 39(3):393–45. Epub 2012/04/17. doi: jrheum.111336 [pii] https://doi.org/10.3899/jrheum.111336 PMID: 22505696.

29. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104(19):2266–8. Epub 2001/11/07. https://doi.org/10.1161/hc401.099447 PMID: 11696462.

30. Sellam J, Proulle V, Jungel A, Ittah M, Miceli Richard C, Gottenberg JE, et al. Increased levels of circulating microparticles in primary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther. 2009; 11(5):R156. Epub 2009/10/17. doi: ar2833 [pii] https://doi.org/10.1186/ar2833 PMID: 19832990; PubMed Central PMCID: PMC2787287.

31. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008; 19(2):146–54. Epub 2007/09/14. doi: 780862256 [pii] https://doi.org/10.1080/09537100701210057 PMID: 17852775.